Middle East Conflict Impacts Australia and New Zealand Businesses 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
DURHAM, N.C., May 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 8:40 a.m. ET at the InterContinental Boston Hotel.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
